

GUIDED THERAPEUTICS INC  
Form 8-K  
December 05, 2012

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event) December 5, 2012; (December 5, 2012)

**GUIDED THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware                                      0-22179                                      58-2029543  
(State or Other Jurisdiction of    (Commission File Number) (IRS Employer Identification No.)

Incorporation)

**5835 Peachtree Corners East, Suite D**

**30092**

**Norcross, Georgia**

(Zip Code)

(Address of Principal Executive Offices)

Registrant's Telephone Number, Including Area Code: **(770) 242-8723**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 7.01 (Regulation FD Disclosure)**

On December 5, 2012, the registrant publicly issued a press release announcing it had successfully completed electromagnetic compatibility testing, one of two major categories of third-party testing, required to label the LuViva® Advanced Cervical Scan with the ISO 60601 Edition 3 CE Mark and Canadian Standards Association (CSA) Mark, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) *Exhibits.*

NumberExhibit

99.1 Press Release dated December 5, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GUIDED THERAPEUTICS, INC.**

By: /s/ Mark L. Faupel, Ph.D.  
Mark L. Faupel, Ph.D.  
CEO & President

Date: December 5, 2012

